Abstract
Select Drug Category: Opiates/Opioids
Topic: Treatment
Abstract Detail: Clinical - Experimental
Abstract Category: Original Research
Aim: Medications for opioid use disorder like buprenorphine remain underutilized despite their effectiveness. To increase engagement in buprenorphine treatment, some programs have begun to adopt more harm-reduction focused approaches that remove many of the barriers that negatively impact treatment engagement. This study examined the prevalence and patient-level indicators of early buprenorphine non-adherence among patients who recently initiated buprenorphine treatment in one such program.
Methods: The sample was comprised of 82 patients who recently (i.e., in the past 28 days) initiated low-barrier office-based buprenorphine treatment at a federally qualified health center located in a large urban city in the mid-Atlantic. At study enrollment, participants completed a psychosocial battery and urine drug screen (UDS). Descriptive statistics were calculated to characterize the sample and identify the prevalence of early buprenorphine non-adherence (i.e., providing buprenorphine-negative UDS within the first month of treatment). Bivariate correlations and logistic regression analysis were used to identify variables associated with early non-adherence.
Results: A significant proportion of participants (n = 24, 29%) displayed early non-adherence based on UDS results. At the bivariate level, non-adherence was positively correlated with SF-36 Physical Functioning (r =.30; p<.05) and Role Limitations-Physical Health (r =.26; p <.05) scores and providing a drug-positive UDS for fentanyl (r =.58; p <.0001), heroin or prescription opioids (r =.43; p <.0001), and cocaine (r =.38; p <.001). Non-adherence was negatively associated with having been prescribed a psychiatric medication (r =.27; p <.05). In the multivariate model, only providing a fentanyl positive UDS reached statistical significance (OR = 10.64, p = <.001).
Conclusions: Findings indicate that almost one-third of patients displayed early buprenorphine non-adherence. Future research is necessary to understand the impact of early non-adherence on longer-term outcomes in low-barrier safety net programs.
Financial Support: Pennsylvania Department of Health SAP#4100083338
Topic: Treatment
Abstract Detail: Clinical - Experimental
Abstract Category: Original Research
Aim: Medications for opioid use disorder like buprenorphine remain underutilized despite their effectiveness. To increase engagement in buprenorphine treatment, some programs have begun to adopt more harm-reduction focused approaches that remove many of the barriers that negatively impact treatment engagement. This study examined the prevalence and patient-level indicators of early buprenorphine non-adherence among patients who recently initiated buprenorphine treatment in one such program.
Methods: The sample was comprised of 82 patients who recently (i.e., in the past 28 days) initiated low-barrier office-based buprenorphine treatment at a federally qualified health center located in a large urban city in the mid-Atlantic. At study enrollment, participants completed a psychosocial battery and urine drug screen (UDS). Descriptive statistics were calculated to characterize the sample and identify the prevalence of early buprenorphine non-adherence (i.e., providing buprenorphine-negative UDS within the first month of treatment). Bivariate correlations and logistic regression analysis were used to identify variables associated with early non-adherence.
Results: A significant proportion of participants (n = 24, 29%) displayed early non-adherence based on UDS results. At the bivariate level, non-adherence was positively correlated with SF-36 Physical Functioning (r =.30; p<.05) and Role Limitations-Physical Health (r =.26; p <.05) scores and providing a drug-positive UDS for fentanyl (r =.58; p <.0001), heroin or prescription opioids (r =.43; p <.0001), and cocaine (r =.38; p <.001). Non-adherence was negatively associated with having been prescribed a psychiatric medication (r =.27; p <.05). In the multivariate model, only providing a fentanyl positive UDS reached statistical significance (OR = 10.64, p = <.001).
Conclusions: Findings indicate that almost one-third of patients displayed early buprenorphine non-adherence. Future research is necessary to understand the impact of early non-adherence on longer-term outcomes in low-barrier safety net programs.
Financial Support: Pennsylvania Department of Health SAP#4100083338
| Original language | English |
|---|---|
| Journal | Drug and Alcohol Dependence |
| Volume | 260 |
| DOIs | |
| State | Published - Jul 1 2024 |
| Event | The College on Problems of Drug Dependence 2023 Annual Scientific Meeting - Denver, United States Duration: Jun 17 2023 → Jun 21 2023 |
Keywords
- buprenorphine
- cocaine
- diamorphine
- fentanyl
- opiate
- adult
- conference abstract
- drug therapy
- harm reduction
- human
- major clinical study
- male
- Pennsylvania
- prescription
- prevalence
- Short Form 36
- therapy